Montelukast potentiates the antiinflammatory effect of NSAIDs in the rat paw formalin model and simultaneously minimizes the risk of gastric damage
Objective and design Montelukast, a cysteinyl leukotriene receptor antagonist, exhibits antiinflammatory action. We tested whether exposure to montelukast plus nonsteroidal antiinflammatory drugs (NSAIDs) elicits better control of paw inflammation in the rat formalin test and improves associated gas...
Gespeichert in:
Veröffentlicht in: | Inflammation research 2021-09, Vol.70 (9), p.981-992 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 992 |
---|---|
container_issue | 9 |
container_start_page | 981 |
container_title | Inflammation research |
container_volume | 70 |
creator | Abdelhady, Sherien A. Ali, Mennatallah A. Al-Shafie, Tamer A. Abdelmawgoud, Ebtsam M. Yacout, Dalia M. El-Mas, Mahmoud M. |
description | Objective and design
Montelukast, a cysteinyl leukotriene receptor antagonist, exhibits antiinflammatory action. We tested whether exposure to montelukast plus nonsteroidal antiinflammatory drugs (NSAIDs) elicits better control of paw inflammation in the rat formalin test and improves associated gastric damage.
Materials
A total of 46 adult male rats were used in the study.
Treatments
We evaluated separate and combined effects of montelukast (20 mg/kg), celecoxib (COX2 inhibitor, 10 mg/kg), and diclofenac (nonselective COX1/COX2 inhibitor, 10 mg/kg) on paw and gastric damage in the rat formalin test.
Results
Individual pretreatments of rats with montelukast, diclofenac, or celecoxib partly reduced formalin-induced increases in (i) paw edema, fibrosis, and inflammatory cells, (iii) serum interleukin-6 (IL-6) and leukotrienes (LTB4 and LTD4), and (iv) paw expressions of inducible nitric oxide synthase (iNOS) and COX2. These effects were accentuated in rats treated with montelukast plus diclofenac or montelukast plus celecoxib. Alternatively, montelukast or celecoxib, but not diclofenac, alleviated formalin-evoked gastric damage and increments in tumor necrosis factor-α and decrements in prostaglandin-E
2
. These advantageous gastric influences were potentiated in rats treated with montelukast plus celecoxib.
Conclusions
While montelukast equally enhances antiinflammatory action of diclofenac or celecoxib via downregulating iNOS/COX2/LTs/IL-6 signaling, its gastroprotective action is preferentially potentiated by celecoxib. |
doi_str_mv | 10.1007/s00011-021-01492-9 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2564322280</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2564322280</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-b04bd56efc521cbe08ec8e14ee890fc9d86e541319f16763befb5f577a7a27633</originalsourceid><addsrcrecordid>eNp9kclOBCEYhInRuL-AB0PiuZWlF_poXCdxOaiJN0J3_4xo04xAx4yv4QuLzqg3DwR--KoqoRDao-SQElIdBUIIpRlhadG8Zlm9gjZpzkhWE_G4ms6E8YwLTjbQVgjPCRdMsHW0wXMuWHrdRB_XbojQjy8qRDxzEYZoVISA4xNglQYz6F5Zq6LzcwxaQxux0_jm7nhyGrAZvkGvkli9Ye28VX26tK6DPuk7HIwd-6gGcGPo59iawVjzvgzwJrx8uU1Tujct7pRVU9hBa1r1AXaX-zZ6OD-7P7nMrm4vJifHV1nLqyJmDcmbrihBtwWjbQNEQCuA5gCiJrqtO1FCkVNOa03LquQN6KbQRVWpSrE08210sPCdefc6Qojy2Y1-SJGSFWXOGWOCJIotqNa7EDxoOfPGKj-XlMivHuSiB5l6kN89yDqJ9pfWY2Oh-5X8fHwC-AII6WmYgv_L_sf2E8H9liQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564322280</pqid></control><display><type>article</type><title>Montelukast potentiates the antiinflammatory effect of NSAIDs in the rat paw formalin model and simultaneously minimizes the risk of gastric damage</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Abdelhady, Sherien A. ; Ali, Mennatallah A. ; Al-Shafie, Tamer A. ; Abdelmawgoud, Ebtsam M. ; Yacout, Dalia M. ; El-Mas, Mahmoud M.</creator><creatorcontrib>Abdelhady, Sherien A. ; Ali, Mennatallah A. ; Al-Shafie, Tamer A. ; Abdelmawgoud, Ebtsam M. ; Yacout, Dalia M. ; El-Mas, Mahmoud M.</creatorcontrib><description>Objective and design
Montelukast, a cysteinyl leukotriene receptor antagonist, exhibits antiinflammatory action. We tested whether exposure to montelukast plus nonsteroidal antiinflammatory drugs (NSAIDs) elicits better control of paw inflammation in the rat formalin test and improves associated gastric damage.
Materials
A total of 46 adult male rats were used in the study.
Treatments
We evaluated separate and combined effects of montelukast (20 mg/kg), celecoxib (COX2 inhibitor, 10 mg/kg), and diclofenac (nonselective COX1/COX2 inhibitor, 10 mg/kg) on paw and gastric damage in the rat formalin test.
Results
Individual pretreatments of rats with montelukast, diclofenac, or celecoxib partly reduced formalin-induced increases in (i) paw edema, fibrosis, and inflammatory cells, (iii) serum interleukin-6 (IL-6) and leukotrienes (LTB4 and LTD4), and (iv) paw expressions of inducible nitric oxide synthase (iNOS) and COX2. These effects were accentuated in rats treated with montelukast plus diclofenac or montelukast plus celecoxib. Alternatively, montelukast or celecoxib, but not diclofenac, alleviated formalin-evoked gastric damage and increments in tumor necrosis factor-α and decrements in prostaglandin-E
2
. These advantageous gastric influences were potentiated in rats treated with montelukast plus celecoxib.
Conclusions
While montelukast equally enhances antiinflammatory action of diclofenac or celecoxib via downregulating iNOS/COX2/LTs/IL-6 signaling, its gastroprotective action is preferentially potentiated by celecoxib.</description><identifier>ISSN: 1023-3830</identifier><identifier>EISSN: 1420-908X</identifier><identifier>DOI: 10.1007/s00011-021-01492-9</identifier><identifier>PMID: 34382102</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject><![CDATA[Acetates - administration & dosage ; Allergology ; Animals ; Anti-inflammatory agents ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Biomedical and Life Sciences ; Biomedicine ; Celecoxib ; Celecoxib - administration & dosage ; COX-2 inhibitors ; Cyclooxygenase 2 - metabolism ; Cyclooxygenase-2 ; Cyclopropanes - administration & dosage ; Damage ; Dermatology ; Diclofenac ; Diclofenac - administration & dosage ; Edema ; Fibrosis ; Formaldehyde ; Formaldehyde - chemistry ; Immunology ; Inflammation ; Inflammation - drug therapy ; Interleukin 6 ; Leukotrienes ; Male ; Montelukast ; Neurology ; Nitric oxide ; Nitric Oxide Synthase Type II - metabolism ; Nitric-oxide synthase ; Nonsteroidal anti-inflammatory drugs ; Original Research Paper ; Pain perception ; Pharmacology/Toxicology ; Quinolines - administration & dosage ; Rats ; Rats, Wistar ; Rheumatology ; Risk ; Rodents ; Signal Transduction ; Stomach - drug effects ; Sulfides - administration & dosage ; Tumor necrosis factor-α]]></subject><ispartof>Inflammation research, 2021-09, Vol.70 (9), p.981-992</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-b04bd56efc521cbe08ec8e14ee890fc9d86e541319f16763befb5f577a7a27633</citedby><cites>FETCH-LOGICAL-c375t-b04bd56efc521cbe08ec8e14ee890fc9d86e541319f16763befb5f577a7a27633</cites><orcidid>0000-0001-8855-7070</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00011-021-01492-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00011-021-01492-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34382102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdelhady, Sherien A.</creatorcontrib><creatorcontrib>Ali, Mennatallah A.</creatorcontrib><creatorcontrib>Al-Shafie, Tamer A.</creatorcontrib><creatorcontrib>Abdelmawgoud, Ebtsam M.</creatorcontrib><creatorcontrib>Yacout, Dalia M.</creatorcontrib><creatorcontrib>El-Mas, Mahmoud M.</creatorcontrib><title>Montelukast potentiates the antiinflammatory effect of NSAIDs in the rat paw formalin model and simultaneously minimizes the risk of gastric damage</title><title>Inflammation research</title><addtitle>Inflamm. Res</addtitle><addtitle>Inflamm Res</addtitle><description>Objective and design
Montelukast, a cysteinyl leukotriene receptor antagonist, exhibits antiinflammatory action. We tested whether exposure to montelukast plus nonsteroidal antiinflammatory drugs (NSAIDs) elicits better control of paw inflammation in the rat formalin test and improves associated gastric damage.
Materials
A total of 46 adult male rats were used in the study.
Treatments
We evaluated separate and combined effects of montelukast (20 mg/kg), celecoxib (COX2 inhibitor, 10 mg/kg), and diclofenac (nonselective COX1/COX2 inhibitor, 10 mg/kg) on paw and gastric damage in the rat formalin test.
Results
Individual pretreatments of rats with montelukast, diclofenac, or celecoxib partly reduced formalin-induced increases in (i) paw edema, fibrosis, and inflammatory cells, (iii) serum interleukin-6 (IL-6) and leukotrienes (LTB4 and LTD4), and (iv) paw expressions of inducible nitric oxide synthase (iNOS) and COX2. These effects were accentuated in rats treated with montelukast plus diclofenac or montelukast plus celecoxib. Alternatively, montelukast or celecoxib, but not diclofenac, alleviated formalin-evoked gastric damage and increments in tumor necrosis factor-α and decrements in prostaglandin-E
2
. These advantageous gastric influences were potentiated in rats treated with montelukast plus celecoxib.
Conclusions
While montelukast equally enhances antiinflammatory action of diclofenac or celecoxib via downregulating iNOS/COX2/LTs/IL-6 signaling, its gastroprotective action is preferentially potentiated by celecoxib.</description><subject>Acetates - administration & dosage</subject><subject>Allergology</subject><subject>Animals</subject><subject>Anti-inflammatory agents</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Celecoxib</subject><subject>Celecoxib - administration & dosage</subject><subject>COX-2 inhibitors</subject><subject>Cyclooxygenase 2 - metabolism</subject><subject>Cyclooxygenase-2</subject><subject>Cyclopropanes - administration & dosage</subject><subject>Damage</subject><subject>Dermatology</subject><subject>Diclofenac</subject><subject>Diclofenac - administration & dosage</subject><subject>Edema</subject><subject>Fibrosis</subject><subject>Formaldehyde</subject><subject>Formaldehyde - chemistry</subject><subject>Immunology</subject><subject>Inflammation</subject><subject>Inflammation - drug therapy</subject><subject>Interleukin 6</subject><subject>Leukotrienes</subject><subject>Male</subject><subject>Montelukast</subject><subject>Neurology</subject><subject>Nitric oxide</subject><subject>Nitric Oxide Synthase Type II - metabolism</subject><subject>Nitric-oxide synthase</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Original Research Paper</subject><subject>Pain perception</subject><subject>Pharmacology/Toxicology</subject><subject>Quinolines - administration & dosage</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Rheumatology</subject><subject>Risk</subject><subject>Rodents</subject><subject>Signal Transduction</subject><subject>Stomach - drug effects</subject><subject>Sulfides - administration & dosage</subject><subject>Tumor necrosis factor-α</subject><issn>1023-3830</issn><issn>1420-908X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kclOBCEYhInRuL-AB0PiuZWlF_poXCdxOaiJN0J3_4xo04xAx4yv4QuLzqg3DwR--KoqoRDao-SQElIdBUIIpRlhadG8Zlm9gjZpzkhWE_G4ms6E8YwLTjbQVgjPCRdMsHW0wXMuWHrdRB_XbojQjy8qRDxzEYZoVISA4xNglQYz6F5Zq6LzcwxaQxux0_jm7nhyGrAZvkGvkli9Ye28VX26tK6DPuk7HIwd-6gGcGPo59iawVjzvgzwJrx8uU1Tujct7pRVU9hBa1r1AXaX-zZ6OD-7P7nMrm4vJifHV1nLqyJmDcmbrihBtwWjbQNEQCuA5gCiJrqtO1FCkVNOa03LquQN6KbQRVWpSrE08210sPCdefc6Qojy2Y1-SJGSFWXOGWOCJIotqNa7EDxoOfPGKj-XlMivHuSiB5l6kN89yDqJ9pfWY2Oh-5X8fHwC-AII6WmYgv_L_sf2E8H9liQ</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Abdelhady, Sherien A.</creator><creator>Ali, Mennatallah A.</creator><creator>Al-Shafie, Tamer A.</creator><creator>Abdelmawgoud, Ebtsam M.</creator><creator>Yacout, Dalia M.</creator><creator>El-Mas, Mahmoud M.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0001-8855-7070</orcidid></search><sort><creationdate>20210901</creationdate><title>Montelukast potentiates the antiinflammatory effect of NSAIDs in the rat paw formalin model and simultaneously minimizes the risk of gastric damage</title><author>Abdelhady, Sherien A. ; Ali, Mennatallah A. ; Al-Shafie, Tamer A. ; Abdelmawgoud, Ebtsam M. ; Yacout, Dalia M. ; El-Mas, Mahmoud M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-b04bd56efc521cbe08ec8e14ee890fc9d86e541319f16763befb5f577a7a27633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acetates - administration & dosage</topic><topic>Allergology</topic><topic>Animals</topic><topic>Anti-inflammatory agents</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Celecoxib</topic><topic>Celecoxib - administration & dosage</topic><topic>COX-2 inhibitors</topic><topic>Cyclooxygenase 2 - metabolism</topic><topic>Cyclooxygenase-2</topic><topic>Cyclopropanes - administration & dosage</topic><topic>Damage</topic><topic>Dermatology</topic><topic>Diclofenac</topic><topic>Diclofenac - administration & dosage</topic><topic>Edema</topic><topic>Fibrosis</topic><topic>Formaldehyde</topic><topic>Formaldehyde - chemistry</topic><topic>Immunology</topic><topic>Inflammation</topic><topic>Inflammation - drug therapy</topic><topic>Interleukin 6</topic><topic>Leukotrienes</topic><topic>Male</topic><topic>Montelukast</topic><topic>Neurology</topic><topic>Nitric oxide</topic><topic>Nitric Oxide Synthase Type II - metabolism</topic><topic>Nitric-oxide synthase</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Original Research Paper</topic><topic>Pain perception</topic><topic>Pharmacology/Toxicology</topic><topic>Quinolines - administration & dosage</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Rheumatology</topic><topic>Risk</topic><topic>Rodents</topic><topic>Signal Transduction</topic><topic>Stomach - drug effects</topic><topic>Sulfides - administration & dosage</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdelhady, Sherien A.</creatorcontrib><creatorcontrib>Ali, Mennatallah A.</creatorcontrib><creatorcontrib>Al-Shafie, Tamer A.</creatorcontrib><creatorcontrib>Abdelmawgoud, Ebtsam M.</creatorcontrib><creatorcontrib>Yacout, Dalia M.</creatorcontrib><creatorcontrib>El-Mas, Mahmoud M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Inflammation research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdelhady, Sherien A.</au><au>Ali, Mennatallah A.</au><au>Al-Shafie, Tamer A.</au><au>Abdelmawgoud, Ebtsam M.</au><au>Yacout, Dalia M.</au><au>El-Mas, Mahmoud M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Montelukast potentiates the antiinflammatory effect of NSAIDs in the rat paw formalin model and simultaneously minimizes the risk of gastric damage</atitle><jtitle>Inflammation research</jtitle><stitle>Inflamm. Res</stitle><addtitle>Inflamm Res</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>70</volume><issue>9</issue><spage>981</spage><epage>992</epage><pages>981-992</pages><issn>1023-3830</issn><eissn>1420-908X</eissn><abstract>Objective and design
Montelukast, a cysteinyl leukotriene receptor antagonist, exhibits antiinflammatory action. We tested whether exposure to montelukast plus nonsteroidal antiinflammatory drugs (NSAIDs) elicits better control of paw inflammation in the rat formalin test and improves associated gastric damage.
Materials
A total of 46 adult male rats were used in the study.
Treatments
We evaluated separate and combined effects of montelukast (20 mg/kg), celecoxib (COX2 inhibitor, 10 mg/kg), and diclofenac (nonselective COX1/COX2 inhibitor, 10 mg/kg) on paw and gastric damage in the rat formalin test.
Results
Individual pretreatments of rats with montelukast, diclofenac, or celecoxib partly reduced formalin-induced increases in (i) paw edema, fibrosis, and inflammatory cells, (iii) serum interleukin-6 (IL-6) and leukotrienes (LTB4 and LTD4), and (iv) paw expressions of inducible nitric oxide synthase (iNOS) and COX2. These effects were accentuated in rats treated with montelukast plus diclofenac or montelukast plus celecoxib. Alternatively, montelukast or celecoxib, but not diclofenac, alleviated formalin-evoked gastric damage and increments in tumor necrosis factor-α and decrements in prostaglandin-E
2
. These advantageous gastric influences were potentiated in rats treated with montelukast plus celecoxib.
Conclusions
While montelukast equally enhances antiinflammatory action of diclofenac or celecoxib via downregulating iNOS/COX2/LTs/IL-6 signaling, its gastroprotective action is preferentially potentiated by celecoxib.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>34382102</pmid><doi>10.1007/s00011-021-01492-9</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-8855-7070</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1023-3830 |
ispartof | Inflammation research, 2021-09, Vol.70 (9), p.981-992 |
issn | 1023-3830 1420-908X |
language | eng |
recordid | cdi_proquest_journals_2564322280 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Acetates - administration & dosage Allergology Animals Anti-inflammatory agents Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Biomedical and Life Sciences Biomedicine Celecoxib Celecoxib - administration & dosage COX-2 inhibitors Cyclooxygenase 2 - metabolism Cyclooxygenase-2 Cyclopropanes - administration & dosage Damage Dermatology Diclofenac Diclofenac - administration & dosage Edema Fibrosis Formaldehyde Formaldehyde - chemistry Immunology Inflammation Inflammation - drug therapy Interleukin 6 Leukotrienes Male Montelukast Neurology Nitric oxide Nitric Oxide Synthase Type II - metabolism Nitric-oxide synthase Nonsteroidal anti-inflammatory drugs Original Research Paper Pain perception Pharmacology/Toxicology Quinolines - administration & dosage Rats Rats, Wistar Rheumatology Risk Rodents Signal Transduction Stomach - drug effects Sulfides - administration & dosage Tumor necrosis factor-α |
title | Montelukast potentiates the antiinflammatory effect of NSAIDs in the rat paw formalin model and simultaneously minimizes the risk of gastric damage |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T10%3A39%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Montelukast%20potentiates%20the%20antiinflammatory%20effect%20of%20NSAIDs%20in%20the%20rat%20paw%20formalin%20model%20and%20simultaneously%20minimizes%20the%20risk%20of%20gastric%20damage&rft.jtitle=Inflammation%20research&rft.au=Abdelhady,%20Sherien%20A.&rft.date=2021-09-01&rft.volume=70&rft.issue=9&rft.spage=981&rft.epage=992&rft.pages=981-992&rft.issn=1023-3830&rft.eissn=1420-908X&rft_id=info:doi/10.1007/s00011-021-01492-9&rft_dat=%3Cproquest_cross%3E2564322280%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2564322280&rft_id=info:pmid/34382102&rfr_iscdi=true |